Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
2000-01-20
2000-11-07
Seaman, D. Margaret
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514397, 546157, 5483114, A61K 3147, A61K 31415, C07D21516, C07D23302
Patent
active
061437662
ABSTRACT:
The present invention provides ras farnesyl transferase inhibiting compounds of Formula I ##STR1## The present invention also provides a method of treating cancer and treating or preventing restenosis or atherosclerosis. Also provided by the present invention is a pharmaceutically acceptable composition containing a compound of Formula I.
REFERENCES:
patent: 4690932 (1987-09-01), Kojima
patent: 5073563 (1991-12-01), Frickel
patent: 5227392 (1993-07-01), Frickel
Abyshev, A. Z., et al., "Synthesis and Biological Activity of Derivatives of Benzopyran-2-One", Pharm. Chem. J., vol. 27, No. 11, 1993, pp. 766-770.
Abyshev, A. Z., et al., "Synthesis and Biological Activity of Benzopyran-2-one Derivatives", Russia Khim-Farm. Zh., vol. 27, No. 11, 1993, pp. 34-38.
Kaltenbronn James Stanley
Leonard Daniele Marie
Repine Joseph Thomas
Ashbrook Charles W.
Seaman D. Margaret
Warner-Lambert & Company
LandOfFree
Benzopyranone and quinolone inhibitors of ras farnesyl transfera does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzopyranone and quinolone inhibitors of ras farnesyl transfera, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzopyranone and quinolone inhibitors of ras farnesyl transfera will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1641482